Comparison of Non-Invasive Clinical Algorithms for Liver Fibrosis in Patients With Chronic Hepatitis B to Reduce the Need for Liver Biopsy: Application of Enhanced Liver Fibrosis and Mac-2 Binding Protein Glycosylation Isomer

다국어 초록 (Multilingual Abstract)

Background: Non-invasive clinical algorithms for the detection of liver fibrosis (LF) can reduce the need for liver biopsy (LB). We explored the implementation of two serum biomarkers, enhanced liver fibrosis (ELF) and Mac-2 binding protein glycosylation isomer (M2BPGi), in clinical algorithms for LF in chronic hepatitis B (CHB) patients.
Methods: Two clinical algorithms were applied to 152 CHB patients: (1) transient elastography (TE) followed by biomarkers (TE/ELF and TE/M2GPGi); (2) biomarker test followed by TE (ELF/TE and M2BPGi/TE). Using the cut-off value or index for the detection of advanced LF (TE≥F3; 9.8 in ELF and 3.0 in M2BPGi), LB was expected to be performed in cases with discordant TE and biomarker results.
Results: In both algorithms, the expected number of LBs was lower when using M2BPGi than when using ELF (TE/ELF or ELF/TE, 13.2% [N=20]; TE/M2BPGi or M2BPGi/TE, 9.9% [N=15]), although there was no statistical difference (P=0.398). In the TE low-risk group (TE≤F2), the discordance rate was significantly lower in the TE/M2BPGi approach than in the TE/ELF approach (1.5% [2/136] vs. 11.0% [15/136], P=0.002). In the biomarker low-risk group, there was no significant difference between the ELF/TE and M2BPGi/TE approaches (3.9% [5/126] vs. 8.8% [13/147], P=0.118).
Conclusions: Both ELF and M2BPGi can be implemented in non-invasive clinical algorithms for assessing LF in CHB patients. Given the lowest possibility of losing advanced LF cases in the low-risk group when using the TE/M2BPGi approach, this combination seems useful in clinical practice.

참고문헌 (Reference)

1 Lichtinghagen R, "influence factors and proposed cut-offvalues" 59 : 236-242, 2013

2 문희원 ; 박미경 ; 허미나 ; 김한아 ; 최원혁 ; 윤여민, "Usefulness of Enhanced Liver Fibrosis, Glycosylation Isomer of Mac-2 Binding Protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for Assessing Liver Fibrosis in Chronic Liver Diseases" 대한진단검사의학회 38 (38): 331-337, 2018

3 Tapper EB, "Use of liver imaging and biopsy in clinical practice" 377 : 2296-2297, 2017

4 Sim J, "The kappa statistic in reliability studies: use, interpretation, and sample size requirements" 85 : 257-268, 2005

5 Petta S, "The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease" 35 : 1566-1573, 2015

6 김혜영, "Statistical notes for clinical researchers: Sample size calculation 2. Comparison of two independent proportions" 대한치과보존학회 41 (41): 154-156, 2016

7 Rousselet MC, "Sources of variability in histological scoring of chronic viral hepatitis" 41 : 257-264, 2005

8 Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5 year open-label follow up study" 381 : 468-475, 2013

9 Castéra L, "Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C" 52 : 191-198, 2010

10 Korean Association for the Study of the Liver, "Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines 2021"

11 Wong GL, "Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B" 39 : 197-208, 2014

12 Soresi M, "Non invasive tools for the diagnosis of liver cirrhosis" 20 : 18131-18150, 2014

13 Liu T, "Molecular serum markers of liver fibrosis" 7 : 105-117, 2012

14 Shirabe K, "Mac-2 binding protein glycan isomer(M2BPGi)is a new serum biomarker for assessing liver fibrosis : more than a biomarker of liver fibrosis" 53 : 819-826, 2018

15 조선영 ; 허미나, "Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis" 대한진단검사의학회 38 (38): 289-290, 2018

16 Calès P, "Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C : agreement or combination?" 45 : 991-1003, 2017

17 Pellicoro A, "Liver fibrosis and repair : immune regulation of wound healing in a solid organ" 14 : 181-194, 2014

18 Bravo AA, "Liver biopsy" 344 : 495-500, 2001

19 Kim MN, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis" 61 : 1851-1859, 2015

20 Faul F, "G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences" 39 : 175-191, 2007

21 Rockey DC, "Fibrosis—a common pathway to organ injury and failure" 372 : 1138-1149, 2015

22 Tsochatzis EA, "Elastography for the diagnosis of severity of fibrosis in chronic liver disease : a meta-analysis of diagnostic accuracy" 54 : 650-659, 2011

23 European Association for Study of Liver, "EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis" 63 : 237-264, 2015

24 Jang Se Young ; Tak Won Young ; Park Soo Young ; Kweon Young-Oh ; Lee Yu Rim ; Kim Gyeonghwa ; Hur Keun ; Han Man-Hoon ; Lee Won Kee, "Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases" 대한진단검사의학회 41 (41): 302-309, 2021

25 Dong Wook Jekarl ; 최현주 ; 이승옥 ; 권정현 ; 이성원 ; 유혜인 ; 김명신 ; 김용구 ; 성필수 ; 윤승규, "Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFAM2BP) Among Chronic Hepatitis B Patients" 대한진단검사의학회 38 (38): 348-354, 2018

26 Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection" 43 : 1317-1325, 2006

27 Narimatsu H, "Development of M2BPGi : a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics" 12 : 683-693, 2015

28 Friedrich-Rust M, "Critical comparison of elastography methods to assess chronic liver disease" 13 : 402-411, 2016

29 Yoneda M, "Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods" 53 : 181-196, 2018

30 Ellis EL, "Clinical evidence for the regression of liver fibrosis" 56 : 1171-1180, 2012

31 Kim SU, "Clinical application of liver stiffness measurement using transient elastography : a surgical perspective" 88 : 258-265, 2013

32 Tamaki Nobuharu ; Kurosaki Masayuki ; Loomba Rohit ; Izumi Namiki, "Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases" 대한진단검사의학회 41 (41): 16-24, 2021

33 World Health Organization, "At last a global response to viral hepatitis"

34 Inadomi C, "Accuracy of the enhanced liver fibrosis test, and combination of the enhanced liver fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease" 50 : 682-692, 2020

35 Boursier J, "A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis" 66 : 1158-1165, 2017

36 Kuno A, "A serum"sweet-doughnut"protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis" 3 : 1065-, 2013